We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

40 hedge funds and large institutions have $103M invested in Protagonist Therapeutics in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

5% more funds holding

Funds holding: 38 → 40 (+2)

0.04% less ownership

Funds ownership: 47.74% → 47.7% (-0.04%)

27% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 15

41% less capital invested

Capital invested by funds: $175M → $103M (-$72.2M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
40
Holders Change
+2
Holders Change %
+5.26%
% of All Funds
1%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
7
Increased
11
Reduced
15
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
BlackRock
New York
+$5.57M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.01M
3
PC
Polar Capital
United Kingdom
+$403K
4
PP
PDT Partners
New York
+$290K
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$178K

Top Sellers

1
DCM
DAFNA Capital Management
California
-$1M
2
RCM
RA Capital Management
Massachusetts
-$908K
3
CAM
Cormorant Asset Management
Massachusetts
-$587K
4
Morgan Stanley
Morgan Stanley
New York
-$208K
5
Citigroup
Citigroup
New York
-$121K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$32.3M +$178K +11,031 +0.4%
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$21.2M +$2.01M +125,000 +8%
PI
3
Pharmstandard International
Luxembourg
$12.6M -$20.9K -1,300 -0.1%
CAM
4
Cormorant Asset Management
Massachusetts
$8.76M -$587K -36,400 -5%
RCM
5
RA Capital Management
Massachusetts
$8.15M -$908K -56,315 -8%
FCMI
6
Foresite Capital Management III
California
$4.44M – – –
BlackRock
7
BlackRock
New York
$4.43M +$5.57M +345,383 +131,826%
Vanguard Group
8
Vanguard Group
Pennsylvania
$4.02M +$55.4K +3,435 +1%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$1.3M +$29.8K +1,850 +2%
State Street
10
State Street
Massachusetts
$1.19M +$14.5K +900 +1%
Northern Trust
11
Northern Trust
Illinois
$1.02M -$40.5K -2,514 -3%
GAMA
12
Graticule Asia Macro Advisors
New York
$408K – – –
SIM
13
Spark Investment Management
New York
$403K – – –
Bank of New York Mellon
14
Bank of New York Mellon
New York
$335K +$55.3K +3,433 +15%
PC
15
Polar Capital
United Kingdom
$320K +$403K +25,000 New
TCIM
16
TIAA CREF Investment Management
New York
$251K -$54.1K -3,358 -15%
PP
17
PDT Partners
New York
$231K +$290K +18,000 New
California State Teachers Retirement System (CalSTRS)
18
California State Teachers Retirement System (CalSTRS)
California
$196K -$6.45K -400 -3%
Charles Schwab
19
Charles Schwab
California
$170K – – –
Morgan Stanley
20
Morgan Stanley
New York
$127K -$208K -12,877 -57%
TA
21
Teachers Advisors
New York
$121K – – –
JP Morgan Chase
22
JP Morgan Chase
New York
$118K -$22.8K -1,413 -13%
New York State Common Retirement Fund
23
New York State Common Retirement Fund
New York
$97K +$122K +7,601 New
Manulife (Manufacturers Life Insurance)
24
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$93K +$23.9K +1,481 +26%
Deutsche Bank
25
Deutsche Bank
Germany
$83K +$35.7K +2,213 +51%
1
2

PTGX Hedge Fund Activity: Q1 2017 in Review

40 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2017, worth a combined $103M — down 41% from $175M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new PTGX positions and 1 closed out — a net gain of 6 holders — while 11 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $5.57M. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $1M sold.

  • 40 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2017, up from 38 in Q4 2016.
  • Funds reported $103M of Protagonist Therapeutics stock for Q1 2017, down 41% quarter-over-quarter.
  • 7 funds opened new Protagonist Therapeutics positions in Q1 2017 and 1 closed out, a net change of +6 holders.
  • The largest Protagonist Therapeutics buyer in Q1 2017 was BlackRock, an estimated $5.57M added.
  • The largest Protagonist Therapeutics seller in Q1 2017 was DAFNA Capital Management, an estimated $1M sold.

Based on aggregated 13F filings for Q1 2017.